Tear production begins with a gland, but the decision to produce tears is partly a neurological event.

To understand why, it helps to follow the path of a signal.

The cornea is densely supplied with sensory nerve endings that continually monitor conditions at the ocular surface. When those nerves detect changes such as evaporation, cooling, mechanical irritation, or injury, information travels toward the brain through the ophthalmic division of the trigeminal nerve.

From there, neural pathways help coordinate protective responses.

Signals can contribute to blinking, eyelid closure, and secretion from the lacrimal glands. Together, these responses help restore a stable environment across the ocular surface.

This is often described as part of the lacrimal functional unit, but thinking of it as a feedback loop makes the biology easier to understand.

The surface detects a change. Sensory nerves report it. The nervous system processes the information. Secretory and motor pathways respond. Tears and blinking then modify conditions at the surface, where sensory nerves continue monitoring what happens next.

The cycle repeats continuously.

In a healthy eye, most of this regulation occurs without conscious awareness. We notice it only when the system is pushed hard enough to generate obvious tearing, blinking, discomfort, or pain.

oGVHD can interfere with several points in this loop.

The lacrimal glands may become inflamed or fibrotic, limiting their ability to respond adequately even when the ocular surface requires more protection. The corneal epithelium may become damaged, changing the environment around sensory nerves. Persistent inflammation and tear-film instability may alter the sensory signals being generated.

That makes the trigeminal pathway scientifically relevant to more than pain.

It is part of the control system that helps regulate ocular surface protection.

This perspective also helps explain why tear production should not be thought of purely as a plumbing problem. A gland does not simply release a fixed amount of fluid throughout the day. Its activity is influenced by neural input responding to what is happening at the surface.

For researchers, this creates an important area of investigation.

If disease affects the sensory side of the loop, the glandular side, or both, understanding where the disruption occurs may help explain differences between patients. It may also help identify new ways to support the ocular surface by working with the body’s own regulatory pathways.

In oGVHD, the eye is a target of immune disease.

But it remains, at the same time, part of a sophisticated sensory system.

The trigeminal nerve is one of the principal pathways connecting those two realities.

This article is for educational purposes only and is not medical advice.

Sources:

1. Belmonte C, Nichols JJ, Cox SM, et al. “TFOS DEWS II Pain and Sensation Report.” The Ocular Surface, 2017.
2. Dartt DA. “Neural regulation of lacrimal gland secretory processes: relevance in dry eye diseases.” Progress in Retinal and Eye Research, 2009.
3. Craig JP, Nichols KK, Akpek EK, et al. “TFOS DEWS II Definition and Classification Report.” The Ocular Surface, 2017.
   https://www.tfosdewsreport.org/report-definition_and_classification/48_36/en/

Patients recovering from an allogeneic hematopoietic stem cell transplant become accustomed to milestones. Days, weeks, and months after transplantation carry meaning. Laboratory values are tracked. Medications change. Infection risks evolve. Follow-up schedules shift. It would be convenient if ocular GVHD followed an equally predictable timetable. It does not.

Chronic oGVHD often emerges after the immediate transplant period, but the timing varies considerably among patients. Ocular symptoms may develop alongside chronic GVHD in other organs, after systemic disease has already been recognized, or as part of a gradually evolving post-transplant course.

This variability is one reason persistent eye symptoms can be easy to underestimate. Months after transplant, dryness may not immediately seem connected to the original procedure. A patient may attribute burning or grittiness to indoor air, medication, screen use, seasonal changes, fatigue, or simply getting older.

Those explanations may sometimes contribute, but transplant history remains clinically important long after the acute recovery period has ended. Modern GVHD classification itself has moved away from relying on a simple day-100 boundary to distinguish disease categories. Clinical characteristics are more meaningful than an arbitrary date. The same principle helps when thinking about the eyes. oGVHD develops through biology, not a calendar.

Immune dysregulation, inflammation, glandular injury, tissue remodeling, and fibrosis unfold differently from patient to patient. Some changes may occur before a person notices substantial symptoms. Others may progress slowly enough that the patient adapts to them. This creates a challenge for both care and research. If follow-up occurs only after significant ocular symptoms develop, earlier changes may be missed. If researchers enroll patients at very different stages of disease, they may also be studying biologically different situations under the same diagnostic label. Longitudinal observation can help bridge that gap.

Repeated evaluation allows clinicians to understand whether tear production is declining, whether staining is appearing or worsening, whether conjunctival or eyelid changes are developing, and whether supportive-care needs are increasing. For transplant survivors, the practical lesson is not that every episode of eye irritation represents oGVHD. It is that new or persistent ocular symptoms remain relevant even when transplantation feels like an event from the past.Survivorship does not have a fixed expiration date, and neither does the need to pay attention to organ complications associated with chronic GVHD. The eyes are part of that long-term story.

This article is for educational purposes only and is not medical advice.

Sources:

1. Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. “Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation.” Biology of Blood and Marrow Transplantation, 2019.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC6362842/
2. Jagasia MH, Greinix HT, Arora M, et al. “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report.” Biology of Blood and Marrow Transplantation, 2015.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC4329079/
3. Tappeiner C, Heiligenhaus A, Halter JP, et al. “Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.” Frontiers in Medicine, 2023.
   https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1133381/full

How do you measure the severity of a disease when the clinical examination tells only part of the story?

That problem has shaped the way ocular graft-versus-host disease is assessed.

In chronic GVHD, the National Institutes of Health developed an organ scoring system that includes the eyes. The ocular score ranges from no symptoms to severe disease, but one of its most important features is what it does not rely on exclusively.

It does not define severity simply by looking at the eye.

Instead, the NIH eye score incorporates the patient’s symptoms, the intensity of supportive care required, and the extent to which ocular disease interferes with daily life.

That approach reflects an important reality of oGVHD. The consequences of the disease are experienced over many hours of the day, while a clinical examination captures only a brief period of time.

A patient may arrive at an appointment after using lubricating drops repeatedly that morning. Another may have adapted daily routines around severe light sensitivity or discomfort. Someone else may be able to read the eye chart in the examination room but struggle to sustain visual tasks for long periods because the tear film rapidly becomes unstable.

These experiences matter when determining how burdensome the disease has become.

The NIH system therefore uses the level of supportive care as part of its assessment. Needing occasional lubrication represents a different disease burden from requiring drops many times a day, specialized eyewear, or other intensive measures simply to function comfortably.

At the more severe end of the scale, ocular symptoms may significantly interfere with activities of daily living.

That does not make the NIH eye score a complete measure of oGVHD biology.

It cannot tell researchers exactly how much inflammation is present in the lacrimal gland, whether fibrosis is progressing, how corneal nerves are behaving, or which molecular pathways are active.

Other tests and measurements are needed for those questions.

What the NIH score contributes is a recognition that severity is not identical to appearance.

A chronic disease can be clinically important because of what it requires from the patient every day.

This distinction is especially valuable in oGVHD because signs and symptoms do not always move together. A patient’s corneal staining may improve without fully resolving discomfort. Tear production may remain low even as another part of the ocular surface improves. Conversely, symptoms may be severe before visible tissue damage becomes extensive.

For research, these differences make endpoint selection difficult.

For patients, they reinforce something more straightforward. The amount of effort required to manage the eyes is itself meaningful information.

A measurement of disease should ultimately reflect not only what clinicians can see, but also what the patient must do to live with it.

The NIH eye score was designed with that principle in mind.

This article is for educational purposes only and is not medical advice.

Sources:

1. Jagasia MH, Greinix HT, Arora M, et al. “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report.” Biology of Blood and Marrow Transplantation, 2015.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC4329079/
2. Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. “Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation.” Biology of Blood and Marrow Transplantation, 2019.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC6362842/

The cornea is transparent by design. That is essential for vision, but it can make early surface damage difficult to appreciate with the naked eye. Ocular surface staining gives clinicians a way to make some of that damage visible.

During an eye examination, a diagnostic dye such as fluorescein can be applied to the ocular surface. Under specialized illumination, areas where the corneal epithelium has been disrupted or compromised become easier to identify. What was nearly invisible can suddenly appear as a pattern of small stained areas across the surface.

In oGVHD, those patterns can tell part of the story of what happens when the eye’s protective systems begin to fail. The healthy cornea is protected by more than tears alone. The tear film must spread evenly, remain stable between blinks, reduce friction from the eyelids, support epithelial cells, and create an environment in which small injuries can repair themselves.

oGVHD can interfere with several of those functions at once. Lacrimal gland dysfunction may reduce tear volume. Meibomian gland abnormalities can increase evaporation. Conjunctival disease may impair mucin support. Inflammation can make the surface more vulnerable, while repeated blinking over an inadequately lubricated cornea can add mechanical stress.

Over time, the epithelium can begin to show the consequences. Staining therefore becomes more than a diagnostic technique. It is a visible record of a surface that is no longer being protected as effectively as it should be.

The amount and pattern of staining can help clinicians assess disease severity and follow changes over time. In clinical research, staining can also serve as an objective measure when investigators are trying to determine whether a therapy is improving the physical condition of the ocular surface.

But staining has its own limitations.

A heavily stained cornea does not tell clinicians exactly how much pain a patient is experiencing. Conversely, relatively modest staining does not mean symptoms must be mild. Ocular sensation is influenced by the dense network of nerves within the cornea, and symptoms can vary substantially between individuals.

That is why staining is most useful when it is treated as one layer of evidence rather than a final verdict.

For patients, the concept can help explain why an ophthalmologist may see clinically meaningful damage even when the eye simply “feels dry.” What the patient experiences as burning, grittiness, light sensitivity, or fluctuating vision may correspond to physical stress on the epithelial surface.

For researchers, staining provides something equally valuable: a way to ask whether treatment is doing more than temporarily changing sensation.

Is the cornea itself becoming healthier? In oGVHD, protecting the ocular surface is ultimately about preserving living tissue. Corneal staining allows some of that tissue stress to be seen.

This article is for educational purposes only and is not medical advice.

Sources:

1. Wolffsohn JS, Arita R, Chalmers R, et al. “TFOS DEWS II Diagnostic Methodology Report.” The Ocular Surface, 2017.
   https://www.tfosdewsreport.org/public/images/TFOS_DEWS_II_Diagnostic_method.pdf
2. Tappeiner C, Heiligenhaus A, Halter JP, et al. “Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.” Frontiers in Medicine, 2023.
   https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1133381/full
3. Nassiri N, Eslani M, Panahi N, et al. “Ocular Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation.” Journal of Ophthalmic & Vision Research, 2013.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC3957042/

Ocular graft-versus-host disease can be difficult to diagnose for the same reason it can be difficult to live with: it does not present in exactly the same way in every patient.

One person may develop profound tear deficiency after allogeneic hematopoietic stem cell transplantation. Another may have more prominent inflammation, corneal staining, eyelid disease, or meibomian gland dysfunction. Some patients experience severe symptoms even when the visible findings appear relatively modest. Others may have substantial ocular surface damage before their symptoms fully reflect its severity.

That variability means there is no single test that can answer the question, “Does this patient have oGVHD?”

Instead, diagnosis is built from a clinical picture.

The transplant history provides the essential context. Persistent or newly developing dryness, burning, grittiness, redness, light sensitivity, pain, or fluctuating vision takes on different significance in someone who has undergone an allogeneic transplant, particularly when chronic graft-versus-host disease is present elsewhere in the body.

From there, clinicians evaluate the ocular surface itself. Examination may include the cornea, conjunctiva, eyelids, meibomian glands, tear film, and areas of possible scarring or epithelial injury. Tear production can be measured with tests such as the Schirmer test, while diagnostic dyes can reveal areas of ocular surface damage that may not otherwise be obvious. Tear-film stability, visual function, and the patient’s description of symptoms add further pieces to the picture.

Several diagnostic and severity frameworks have been developed because the field has long recognized that oGVHD cannot be captured by one measurement. The National Institutes of Health criteria, for example, incorporate symptoms and the amount of supportive eye care a patient requires. International consensus approaches have combined symptoms with objective findings such as tear production, corneal staining, and conjunctival changes.

These frameworks are useful, but they also reveal something fundamental about the disease. oGVHD is not one abnormal number. It is a disorder involving an interconnected ocular surface system, and different parts of that system may be affected to different degrees.

That is why diagnosis requires both measurement and interpretation. A low tear-production result matters, but so does the condition of the cornea. Surface staining matters, but so does the patient’s ability to function comfortably. Transplant history matters because it changes the meaning of all those findings.

For patients and advocates, this is an important distinction. An eye examination after transplant is not simply a search for “dry eye.” It is an effort to determine whether the ocular surface is showing evidence of a transplant-related immune disease and, if so, how that disease is affecting the tissues responsible for maintaining comfort and vision.

In oGVHD, the diagnosis comes from understanding the whole eye in the context of the whole patient.

This article is for educational purposes only and is not medical advice.

Sources:

1. Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. “Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation.” Biology of Blood and Marrow Transplantation, 2019.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC6362842/
2. Tappeiner C, Heiligenhaus A, Halter JP, et al. “Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.” Frontiers in Medicine, 2023.
   https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1133381/full
3. Jagasia MH, Greinix HT, Arora M, et al. “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report.” Biology of Blood and Marrow Transplantation, 2015.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC4329079/